vkns’k ubz fnyyh] ] 2018dpco2013.com/files/data/gazattenotification2018/5151532326242.pdf · 2...

3776 GI/2018 (1)

jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99

vlk/kj.k EXTRAORDINARY

Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii)

izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY

la- 2489] ubZ fnYyh] cq/okj] tqykbZ 4] 2018@vk"kk<+ 13] 1940 No. 2489] NEW DELHI, WEDNESDAY, JULY 4 2018/ ASHADHA 13, 1940

jlk;u vkSj moZjd ea=ky;

¼ vkS"k/k foHkkx½

¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½

vkns’k

ubZ fnYyh] 4 जुलाई] 2018 dk- vk-3240¼v½-& Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013

vkSj dk- vk- 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5] 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

dz-la-

vuqlwfpr fofufeZfr dk uke@czkaM dk uke

izcyrk bdkbZ fofuekZrk vkSj foi.ku daiuh

[kqnjk ewY; ¼#-½

(1) (2) (3) (4) (5) (6)

1. jkstwokLVkfVu $ DyksfiMksxzsy dSIlwy ¼ØsokLV lhoh 20½

izR;sd gkMZ tsysVkbu dSIlwy esa% jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstwokLVkfVu 20 fexzk-] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@bfjt ykbQlkbalsl fy-

16.73

2. Q~ywdksuktksy fMLijflcy xksyh ¼vyVhdsu&50 MhVh½

izR;sd vfyfir xksyh esa% Q~ywdksuktksy vkbZih 50 fexzk-

1 xksyh eSllZ ,Des QkWewZys’ku izk-fy-@eSllZ lu QkekZL;wfVdYl baMLVªht fy-

6.24

3. ,eksDlhlhfyu $ DykoqyusV MªkbZ flji ¼DykuksDlh QkWVZ½

izR;sd 5 fefy- iqufufeZr fuyacu esa% ,eksDlhlhfyu VªhgkbMªsV vkbZih ds cjkcj ,eksDlhlyfyu 400 fexzk-] iksVsf’k;e DykoqyusV fMyqfVM vkbZih ds cjkcj Dykoqyfud ,flM 57 fexzk-

1 fefy- eSllZ xSYQk yScksjsVjhr fy- 3.219

2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

4. VsyfelkVZu $ esVksizksyksy xksyh ¼esVksykj Vh,y 25½

izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] esVksizksyksy lqlkbusV vkbZih 47-50 fexzk- ds cjkcj esVksizksyksy VkjVªsV 50 fexzk- ¼bZvkj½

1 xksyh eSllZ jsosuHksy ck;ksVsd fy-

/ eSllZ िस�ला fy- 11.05

5. VsyfelkVZu $ esVksizksyksy xksyh ¼esVksykj Vh,y 25½

izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] esVksizksyksy lqlkbusV vkbZih 23-50 fexzk- ds cjkcj esVksizksyksy VkjVªsV 25 fexzk- ¼bZvkj½

1 xksyh eSllZ jsosuHksy ck;ksVsd

fy- / eSllZ िस�ला fy-

9.22

6. gkbMªksDlhDyksjksDohu lYQsV xksyh ¼vks,DllhD;w 300 fexzk-½

izR;sd fQYe fyfir xksyh es% gkbMªksDlhDyksjksDohu lYQsV 300 fexzk-

1 xksyh eSllZ okysl QkekZL;wfVdYl izk- fy-

9.58

7. XyhesfijkbM $ esVQksfeZu xksyh

izR;sd fQYe fyfir fcys;MZ xksyh esa% XyhesfijkbM 3 fexzk-] esVQksfeZu ,lvkj 500 fexzk-

1 xksyh eSllZ fLol xkfuZ;j tsusfDl;k lkbalst@ eSllZ XysuekdZ QkekZL;wfVdYl fy-

6.89

8. XyhesfijkbM $ esVQksfeZu $ oksXyhcksl xksyh

izR;sd fQYe fyfir fcys;MZ xksyh esa% XyhesfijkbM 2 fexzk-] esVQksfeZu ,lvkj 500 fexzk- oksXyhcksl 0-3 fexzk- xksyh


11.01




11.61




9.40

11. VsyfelkVZu $ fdYuhMhikbu $ DyksjFkkyhMksu xksyh

izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] fdYuhMhikbu 10 fexzk- vkSj DyksjFkkyhMksu vkbZih 6-25 fexzk-


10.37

12. Dyksuktsike $ izksizkuksyksy xksyh

izR;sd vfyfir xksyh esa% Dyksuktsike vkbZih 0-50 fexzk-] izksizkuksyksy gkbMªksDyksjkbM vkbZih 20 fexzk-

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,eD;ksj QkekZL;wfVdYl fy-

4.12

13. VsyfelkVZu $ DyksjFkkyhMksu xksyh ¼VsyQk&lh,p½

izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] DyksjFkkyhMksu vkbZih 12-5 fexzk-

1 xksyh eSllZ QkekZQscfjdksu 5.89

14. MksDlks:fclhu gkbMªksDyksjkbM fyikslkse batSD’ku 20 fexzk-@ fefy- ¼20 fexzk-@ok;y½ 10 fefy- ¼isthysfVM fyikslksey½ dulUVªsV QkWj buQ~;wtu

izR;sd fefy- esa% MksDlks:fclhu gkbMªksDyksjkbM 2 fexzk- ¼isxhysfVM fyikslkseky½ okVj QkWj batSD’ku

10 fefy- ok;y

eSllZ ukVdks QkekZ fy-@eSllZ vksjs,V gsYFk izk- fy-

6459.20

15. fdYuhMhikbu $ VsyfelkVZu xksyh ¼flYuhCyw Vh½

fQYe fyfir xksyh esa% fdYuhMhikbu vkbZih 10 fexzk-] VsyfelkVZu vkbZih 40 fexzk-

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy- eSllZ Cyw Øksl yscksjsVjht izk- fy-

4.00

16. lksQkslcqfoj $ osyiVlohj xksyh

izR;sd fQYe fyfir xksyh esa% lksQkslcqfoj 400 fexzk-] osyiVlohj 100 fexzk-

28 xksfy;ka

eSllZ ukVdks QkekZ fy-@ eSllZ ,izktj gsYFk ds;j izk-fy-

15481.86

17. lksQkslcqohj $

लेडपासवीर xksyh izR;sd fQYe fyfir xksyh esa% lksQkslcqfoj 400 fexzk-]

लेडपासवीर 90 fexzk-

1 xksyh eSllZ ukVdks QkekZ fy-@ eSllZ ,izktj gsYFk ds;j izk-fy-

589.92

18. bVksfjdksDlho $ iSjkflVkeksy xksyh

izR;sd fQYe fyfir xksyh esa% bVksfjdksDlho 60 fexzk-] iSjkflVkeksy 325 fexzk-

1 xksyh eSllZ dSfMyk QkekZL;wfVdYl fy-

5.46

19. ,Mkiysu $ csutks,y tSy

‘kkfey gSa% ,Mkiysu chih 0-1% MCY;w@MCY;w csutks,y ijvkDlkbM vkbZih ds cjkcj ,ugkbMªkst csutks,y isjksDlkbM 2-5% MCY;w@MCY;w

1 xzke eSllZ ,isDl yscksjsVjht izk- fy-

18.42

20 VsusfyfXyfIVu $ esVQksfeZu xksyh

izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ

10.09

¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3

¼okykQst Vh 500½ cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼,lvkj½

oSySl QkekZL;wfVdYl izk- fy-

21. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼okykQst Vh 500½

izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼,lvkj½

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ oSySl QkekZL;wfVdYl izk- fy-

9.79

22. fczeksfuMkbu $ fVeksyksy vkbZ MªksIl ¼U;w ,yczhe ,y,lVh½

‘kkfey gSa% fczeksfuMkbu VkjVªkV vkbZih 0-2% MCY;w@oh fVeksyksy ds cjkcj fVeksyksy 5% MCY;w@oh LVsfjy ,D;w,vksl osfgdy D;w-,l

1 fefy- eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,ysefcd QkekZL;wfVDyl fy-

18.75

23. XyhesfijkbM $ esVQksfeZu $ xksyh ¼XykbdksesV thih 3½

izR;sd संशोिधत fcys;MZ xskyh esa% XyhesfijkbM vkbZih 3 fexzk-] esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk- ¼bZvkj½

1 xksyh eSllZ vaQj vkWxsZfuDl@eSllZ ;w,loh izk- fy-

6.89

24. iSdyhVkDlsy ¼izksVhu ckmaM ikfVZdYl½ QkWj butsDVsfcy lLisa’ku

izR;sd ok;y esa% iSdyhVkDlsy vkbZih 100 fexzk-@ok;y

yb;ksfQfytsM g~;qeu ए�बिमन D;w-,l.

izfr iSd eSllZ fcVk MªXl fy-@eSllZ vkjihth ykbQ lkbalst fy-

11590.00

25. XyhesfijkbM $ esVQksfeZu $ xksyh ¼Xyhfelu&,e 0-5½

izR;sd vfyfir fcys;MZ xksyh esa% XyhesfijkbM vkbZih 0-5 fexzk- vkSj

esVQksfeZu ,plh,y vkbZih 500 fexzk- ¼izksykWxM jhfyt QkWeZ esa½

1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl fy-

1.79

26. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼VsusCyw ,e QkWVZ½

izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼,lvkj½

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ Cyw Øksl yscksjsVjht izk- fy-

9.50

27. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼VsusCyw ,e½

izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼,lvkj½

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ Cyw Øksl yscksjsVjht izk- fy-

7.50

28. vksyfelkVZu $ ,eyksfMikbu $ gkbZMªksDyksjksFkkbtkbM xksyh ¼,eyksdkbaM&5)

izR;sd fQYe fyfir xksyh esa% vksyfelkVZu esMksDlksfey vkbZih 40 fexzk-] ,eyksfMikbu fclkbysV vkbZih ds cjkcj ,eyksfMikbu 5 fexzk- vkSj gkbZMªksDyksjksFkkbtkbM vkbZih 12-5

1 xksyh eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ esudkbaM QkekZ fy-

12.95

29. VªkoksizksLV $ fVeksyksy ekys,V $ fcutkydksfu;e vkbZ MªksIl

‘kkfey gSa% VªkoksizksLV vkbZih 0-004% MCY;w@oh] fVeksyksy ekys,V vkbZih ds cjkcj fVeksyksy 0-5% MCY;w@oh] fcutkydksfu;e DyksjkbM lksyq’ku vkbZih 0-01% oh@oh

1 fefy- eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ ykbQ LVkj QkekZ izk- fy-

130.76

30. czheksfuMkbu $ fVeksyksy ekys,V fcutkYdksfu;e vkbZ MªksIl

‘kkfey gSa% czheksfuMkbu VkjVªkV vkbZih 0-2% MCY;w@oh] fVeksyksy ekys,V vkbZih ds cjkcj fVeksyksy 0-5% MCY;w@oh] fcutkydksfu;e DyksjkbM lksyq’ku vkbZih 0-01% oh@oh

1 fefy- eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ ykbQ LVkj QkekZ izk- fy-

21.68

31. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼Xyhihtc ,e QkWVZ½

izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼bZvkj½

1 xksyh eSllZ XysuekdZ QkekZL;wfVdYl fy-@eSllZ tqfcysaV ykbQlkbalst fy-

10.06

32. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼Xyhihtc ,e½

izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼bZvkj½

1 xksyh eSllZ XysuekdZ QkekZL;wfVdYl fy-@eSllZ tqfcysaV ykbQlkbalst fy-

9.79

33. VsusfyfXyfIVu $ esVQksfeZu xksyh

izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼bZvkj½

1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-

6.25

34. VsusfyfXyfIVu $ esVQksfeZu xksyh

izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds


5.358


cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼bZvkj½

35. VªkoksizksLV $ fVeksyksy vkbZ MªksIl ¼VªkfolkbV&Vh½

izR;sd fefy- esa% VªkoksizksLV vkbZih 40 ,elhth] fVeksyksy ekys,V vkbZih ds cjkxj fVeksyksy 5 fexzk-

1 fefy- eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,ysefcd QkekZL;wfVdYl fy-

86.30

36. fdYuhMhikbu $ VsyfelkVZu DyksjFkkyhMksu xksyh

izR;sd fQYe fyfir xksyh esa% fdYuhMhikbu 10 fexzk-] VsyfelkVZu vkbZih 40 fexzk-] DyksjFkkyhMksu 6-25 fexzk-

1 xksyh eSllZ lQsVc ykbQ lkbal@eSllZ yqfiu fy-

10.37

37. VsyfelkVZu $ gkbMªksDyksjFkkbtkbM xksyh ¼VsYQk&,p½

izR;sd vfyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] gkbMªksDyksjFkkbtkbM vkbZih 12-5 fexzk-

1 xksyh eSllZ QkekZQscfjdksu

7.14

38. Qsjl ,LdkscsZV $ Qksfyd ,flM xksyh

izR;sd fQYe fyfir xksyh esa% Qsjl ,LdkscsZV ds cjkcj bysesuVy vk;ju 100 fexzk-] Qksfyd ,flM vkbZih 1-5 fexzk-

1 xksyh eSllZ fr:ifr esfMds;j fy-@eSllZ tsMl dSfMyk gsYFkds;j fy-

8.89

39. MksDlks:fcflu gkbMªksDyksjkbM batSD’ku

izR;sd fefy- esa% MksDlks:fcflu gkbMªksDyksjkbM vkbZih 2 fexzk- ¼fixkbysfVM fyikslksey½ okVj QkWj batSD’ku

25 fefy- ok;y

eSllZ ukVdks QkekZ fy-@eSllZ tsMl dSfMyk gsYFkds;j fy-

13473.68

40. jkstwokLVkfVu $ DyksfiMksxzsy dSIlwy

izR;sd gkMZ tsysVkbu dSIlwy esa% jkstwokLVkfVu vkbZih 20 fexzk- ¼iSysVl esa½] DyksfiMksxzsy vkbZih 75 fexzk- ¼iSysVl esa½

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ baVkl QkekZL;wfVdYl fy-

16.26

41. fdYuhMhikbu $ VsyfelkVZu xksyh ¼usDlkso ,,l Vh½

izR;sd fQYe fyfir xksyh esa% fdYuhMhikbu 10 fexzk- vkSj VsyfelkVZu vkbZih 40 fexzk-

1 xksyh eSllZ esdysM~l QkekZL;wfVdYl fy-

7.67

42. fdYuhMhikbu $ VsyfelkVZu xksyh ¼thVsyeh&lh,y½


1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,QMhlh fy-

7.14

43. fMDyksQsud $ fyulhM vkW;y $ esFkkby lsfylkbysV $ esaFkksy $ csutkby ,Ydksgy tSy ¼Mu½

‘kkfey gSa% fMDyksQsud MkbbfFkykekbu 1-16% MCY;w@MCY;w$ fyulhM vkW;y 3% MCY;w@MCY;w $ esFkkby lkyhlkbysV 10% MCY;w@MCY;w $ esaFkksy 5% MCY;w@MCY;w csutkby ,Ydksgy 1% MCY;w@MCY;w tSy csl D;w-,l

1 xzke eSllZ VqVksu QkekZL;wfVdyl@eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-

1.40

44. VsyfelkVZu $ ,EyksfMikbu xksyh ¼VsyehjkbM& ,,e½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] ,EyksfMikbu 5 fexzk-


2.99

45. fdYuhMhikbu $ VsyfelkVZu xksyh ¼VsyehjkbM& ,y,u½


1 xksyh eSllZ foaMykl ck;ksVsd izk- fy- / eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-

3.57

46. oksXyhcksl $ esVQksfeZu xksyh$ ¼oksXyhlksu&,e 0-2½

izR;sd fcys;MZ xksyh esa% oksXyhcksl 0-2 fexzk- vkSj esVQksfeZu gkbMªksDyksjkbM 500 fexzk-


3.20

47. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 2 ,eoh 0-3½

izR;sd xksyh esa% oksXyhcksl vkbZih 0-3 fexzk-] XyhesfijkbM vkbZih 2 fexzk- vkSj esVQksfeZu ¼,lvkj½ 500 fexzk-

1 xksyh eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ isufl;k ck;ksVsd fy-

9.37


48. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 1 ,eoh 0-3½



8.03

49. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 2 ,eoh½



8.48

50. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 1 ,eoh½



7.14

uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA

¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA

¼?k½vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgt n`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA

¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA

¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA

[dka- la-@190@58/2018@,Q@Qk- la- 8¼58½@2018@Mhih@,uihih,&fMoh-II]

cythr flag] lgk;d funs'kd

MINISTRY OF CHEMICALS AND FERTILIZERS

(Department of Pharmaceuticals)

(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)

ORDER

New Delhi, the 4th July, 2018

S. O. 3240(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued

by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing


Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein

below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in

the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer &

marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

TABLE

Sl.

No.

Name of the

Formulation / Brand

Name

Strength Unit Manufacturer &

Marketing

Company

Retail

Price

(Rs.)

(1) (2) (3) (4) (5) (6)

1. Rosuvastatin +

Clopidogrel Capsule

(Crevast CV 20)

Each Hard gelatine capsule contains:

Rosuvastatin Calcium IP eq. to

Rosuvastatin 20mg,

Clopidogrel Bisulphate IP eq. to

Clopidogrel 75mg.

1 Capsule M/s Synokem

Pharmaceuticals Ltd/

M/s Eris Lifesciences

Ltd.

16.73

2. Fluconazole

Dispersible Tablet

(ULTICAN – 50 DT)

Each uncoated tablet contains:

Fluconazole IP 50mg

1 Tablet M/s Acme

Formulations

Pvt. Ltd. / M/s Sun

Pharmaceutical

Industries Ltd.

6.24

3. Amoxycillin +

Clavulante Dry Syrup

(Clanoxy Forte)

Each 5ml of reconstituted

Suspension:

Amoxycillin Trihydrate IP eq. to

Amoxycillin 400mg, Potassium

Clavulante Diluted IP eq. to

Clavulnic Acid 57mg

1 ML M/s Galpha

Laboratories Limited

3.219

4. Telmisartan +

Metoprolol Tablet

(Metolar TL 50)

Each film coated bilayered tablet

contains:

Telmisartan IP 40mg,

Metoprolol Succinate IP 47.50mg eq.

to Metoprolol Tartrate 50mg (ER)

1 Tablet M/s Revenbhel

Biotech Ltd./

M/s Cipla Ltd.

11.05

5. Telmisartan +

Metoprolol Tablet

(Metolar TL 25)


contains:


Metoprolol Succinate IP 23.50mg eq.

to Metoprolol Tartrate 25mg (ER)

1 Tablet M/s Revenbhel

Biotech Ltd. /

M/s. Cipla Ltd.

9.22

6. Hydroxychloroquine

Sulphate Tablet

(OXCQ 300mg)

Each film coated tablet contains:

Hydroxychloroquine Sulphate

300mg

1 Tablet M/s Wallace

Pharmaceuticals

Pvt. Ltd.

9.58

7. Glimepiride +

Metformin Tablet


contains:

Glimepiride 3mg,

Metformin SR 500mg

1 Tablet M/s Swiss Garnier

Genexiaa Sciences /

M/s Glenmark

Pharmaceuticals Ltd.

6.89

8. Glimepiride +

Metformin +

Voglibose Tablet


contains:

Glimepiride 2mg,

Metformin SR 500mg

Voglibose 0.3mg Tablets


Genexiaa Sciences /

M/s. Glenmark


11.01

9. Glimepiride +

Metformin +

Voglibose Tablet


contains:

Glimepiride 2mg,

Metformin SR 1000mg



Genexiaa Sciences /

M/s. Glenmark


11.61

10. Glimepiride +

Metformin +

Voglibose Tablet


contains:

Glimepiride 1mg,

Metformin SR 500mg



Genexiaa Sciences /

M/s. Glenmark


9.40

11. Telmisartan +

Clinidipine +

Chlorthalidone Tablet


contains:



Genexiaa Sciences /

M/s. Glenmark

10.37


Clinidipine 10mg &

Chlorthalidone IP 6.25mg


12. Clonazepam +

Propranolol Tablet

Each uncoated tablet contains:

Clonazepam IP 0.50mg,

Propranolol Hydrochloride IP 20mg

1 Tablet M/s Akums Drugs &

Pharmaceutical

Limited / M/s

Emcure

Pharmaceuticals

Limited

4.12

13. Telmisartan +

Chlorthalidone

Tablet (Telpha-CH)

Each uncoated bilayered tablet

contains:


Chlorthalidone IP 12.5mg

1 Tablet M/s

Pharmafabrikon

5.89

14. Doxorubicin

Hydrochloride

Liposome Injection

2mg/ml (20mg/vial)

10ml (Pegylated

Liposomal)

Concentrate for

Infusion

Each ml contains:

Doxorubicin Hydrochloride 2mg

(Pegylated Liposomal) Water for

Injection

10 ML vial M/s Natco Pharma

Limited / M/s

Aureate Health

Pvt. Ltd.

6459.20

15. Cilnidipine +

Telmisartan Tablet

(Cilniblu T)


Cilnidipine IP 10mg,

Telmisartan IP 40mg

1 Tablet M/s Akums Drugs

& Pharmaceuticals

Ltd. / M/s Blue

Cross Laboratories

Pvt. Ltd.

4.00

16. Sofosbuvir +

Velpatsvir Tablet


Sofosbuvir 400mg,

Velpatsvir 100mg

28’s Tablets M/s Natco Pharma

Ltd. / M/s Aprazer

Health Care Pvt.

Ltd.

15481.86

17. Sofosbuvir +

Ledipasvir Tablet


Sofosbuvir 400mg,

Ledipasvir 90mg

1 Tablet M/s Natco Pharma

Ltd. / M/s Aprazer

Health Care Pvt.

Ltd.

589.92

18. Etoricoxib +

Paracetamol Tablet


Etoricoxib 60mg,

Paracetamol 325mg

1 Tablet M/s Cadila

Pharmaceuticals

Limited

5.46

19. Adapalene + Benzoyl

Gel

Contains:

Adapalene BP 0.1% w/w

Benzoyl Peroxide IP eq. to

Anhydrous Benzoyl Peroxide

2.5%w/w

1 GM M/s Apex

Laboratories Private

Limited

18.42

20 Teneligliptin +

Metformin Tablet

(Walaphage T 1000)

Each uncoated bilayer tablet

contains:

Teneligliptin Hydrobromide Hydrate

eq. to Teneligliptin 20mg

Metformin HCl 1000mg (SR)

1 Tablet M/s Synokem


/ M/s Wallace

Pharmaceuticals Pvt.

Ltd.

10.09

21. Teneligliptin +

Metformin Tablet

(Walaphage T 500)


contains:






/ M/s Wallace


Ltd.

9.79

22. Brimonidine +

Timolol Eye Drops

(New Albrim LST)

Contains:

Brimonidine Tartrate IP 0.2%w/v,

Timolol Maleate IP eq. to Timolol

0.5% w/v Sterile aqueous vehicle q.s.

1 ML M/s Akums Drugs &


/ M/s Alembic

Pharmaceuticals

Limited

18.75


23. Glimiepiride +

Metformin Tablet

(GLYCOMET GP 3)

Each modified bi-layered ed tablet

contains:

Glimiepiride IP 3mg,

Metformin Hydrochloride IP 500mg

(ER)

1 Tablet M/s Anphar

Organics. / M/s USV

Private Limited

6.89

24. Paclitaxel (Protein

bound Particles) for

Injectable Suspension

Each vial contains:

Paclitaxel IP 100mg/vial Lyophilized

Human albumin q.s.

Each Pack M/s Beta Drugs Ltd /

M/s RPG Life

Sciences Limited

11590.00

25. Glimiepiride +

Metformin Tablet

(Glimison – M 0.5)

Each Uncoated bilayered Tablet

contains:

Glimepiride IP 0.5mg & Metformin

HCL IP 500mg (in prolonged release

form)

1 Tablet M/s Unison

Pharmaceuticals

Limited

1.79

26. Teneligliptin +

Metformin Tablet

(Teneblu M Forte)


contains:






/ M/s Blue Cross

Laboratories Pvt.

Ltd.

9.50

27. Teneligliptin +

Metformin Tablet

(Teneblu M)


contains:






/ M/s Blue Cross

Laboratories Pvt.

Ltd.

7.50

28. Olmesartan +

Amlodipine +

Hydrochlorothiazide

Tablet (Amlokind –

5)


Olmesartan Medoxomil IP 40mg,

Amlodipine Besilate IP eq. to

Amlodipine 5mg &

Hydrochlorothiazide IP 12.5

1 Tablet M/s Pure & Cure

Healthcare Pvt. Ltd. /

M/s Mankind

Pharma Limited

12.95

29. Travoprost + Timolol

Maleate +

Benzalkonium Eye

Drops

Contains:

Travoprost IP 0.004%w/v,


0.5% w/v,

Benzalkonium Chloride Solution IP

0.01% v/v

1 ML M/s Pure & Cure


M/s LifeStar Pharma

Private Limited

130.76

30. Brimonidine +

Timolol Maleate +

Benzalkonium Eye

Drops

Contains:

Brimonidine Tartrate IP 0.2%w/v,


0.5% w/v,

Benzalkonium Chloride Solution IP

0.02% v/v

1 ML M/s Pure & Cure


M/s LifeStar Pharma

Private Limited

21.68

31. Teneligliptin +

Metformin Tablet

(Glipijub M Forte)


contains:



Metformin HCl 1000mg (ER)

1 Tablet M/s Glenmark


/ M/s Jubilant

Lifesciences Limited

10.06

32. Teneligliptin +

Metformin Tablet

(Glipijub M)


contains:




1 Tablet M/s Glenmark


/ M/s Jubilant


9.79

33. Teneligliptin +

Metformin Tablet


contains:




1 Tablet M/s Unison


Ltd.

6.25

34. Teneligliptin +

Metformin Tablet


contains:




1 Tablet M/s Unison


Ltd.

5.358


35. Travoprost + Timolol

Eye Drops

(Travisight –T)

Each ml contains:

Travoprost IP 40mcg,


5mg

1 ML M/s Akums Drugs &


/ M/s Alembic


86.30

36. Cilnidipine +

Telmisartan +

Chlorthalidone Tablet

Each filmcoated tablet contains:

Cilnidipine 10mg,


Chlorthalidone 6.25mg

1 Tablet M/s Safetab Life

Science / M/s Lupin

Limited

10.37

37. Telmisartan +

Hydrochlorthiazide

Tablet (Telpha-H)


contains:


Hydrochlorthiazide IP 12.5mg

1 Tablet M/s Pharmafabrikon

7.14

38. Ferrous Ascorbate +

Folic Acid Tablet


Ferrous Ascorbate eq. to Elemental

Iron 100mg,

Folic Acid IP 1.5mg,

1 Tablet M/s Tirupati

Medicare Ltd / M/s

Zydus Cadila

Healthcare Limited

8.89

39. Doxorubicin

Hydrochloride

Injection

Each ml contains:

Doxorubicin Hydrochloride IP 2mg

(As pegylated liposomal) Water for

Injection

25 ML vial M/s Natco Pharma

Ltd. / M/s Zydus

Cadila Healthcare

Limited

13473.68

40. Rosuvastation +

Clopidogrel Capsule

Each hard gelatine capsule contains:

Rosuvastation IP 20mg (As pellets),

Clopidogrel IP 75mg (as pellets)

1 Capsule M/s Synokem

Pharmaceuticals

Limited / M/s

INTAS

Pharmaceuticals

Limited

16.26

41. Cilnidipine +

Telmisartan Tablet

(NEXOVAS T)


Cilnidipine 10mg &

Telmisartan IP 40mg

1 Tablets M/s Macleods

Pharmaceuticals

Limited

7.67

42. Cilnidipine +

Telmisartan Tablet

(ZITELMI –CL)


Cilnidipine 10mg &

Telmisartan IP 40mg

1 Tablets M/s Akums Drugs &

Pharmaceuticals

Limited / M/s FDC

Limited

7.14

43. Diclofenac + Linseed

Oil + Methyl

Salicylate + Menthol

+ Benzyl Alcohol

GEL (Dan)

contains:

Diclofenac Diethylamine 1.16% w/w

+

Linseed Oil 3% w/w +

Methyl Salicylate 10% w/w

Menthol 5% w/w

Benzyl Alcohol 1% w/w

GEL base q. s.

1 GM M/s Tuton

Pharmaceuticals /

M/s Unison


Ltd.

1.40

44. Telmisartan +

Amlodipine Tablet

(Telmiride – AM)

Each film coated tablets contains:

Telmisartan IP 40mg +

Amlodipine 5mg

1 Tablet M/s Unison


Ltd.

2.99

45. Cilnidipine +

Telmisartan Tablet

(Telmiride – LN)


Cilnidipine 10mg &

Telmisartan IP 40mg

1 Tablet M/s Windlas Biotech

Pvt. Ltd. / M/s

Unison


Ltd.

3.57

46. Voglibose +

Metformin Tablet

(Voglyson – M 0.2)


Contains:

Voglibose 0.2mg &

Metformin Hydrochloride 500mg

1 Tablet M/s Unison


Ltd.

3.20


47. Voglibose +

Glimepiride +

Metformin Tablet

(BETAGLIM 2 MV

0.3)

Each tablets contains:

Voglibose IP 0.3mg,

Glimepiride IP 2mg &

Metformin (SR) 500mg


Pvt. Ltd. / M/s

Panacea Biotech Ltd.

9.37

48. Voglibose +

Glimepiride +

Metformin Tablet

(BETAGLIM 1 MV

0.3)


Voglibose IP 0.3mg,




Pvt. Ltd. / M/s


8.03

49. Voglibose +

Glimepiride +

Metformin Tablet

(BETAGLIM 2 MV)


Voglibose IP 0.2mg,




Pvt. Ltd. / M/s


8.48

50. Voglibose +

Glimepiride +

Metformin Tablet

(BETAGLIM 1 MV)


Voglibose IP 0.2mg,




Pvt. Ltd. / M/s


7.14

Note:

(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the

DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to

the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned

manufacturer in accordance with the retail price specified in column (6) of the above table as per

provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in

Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS

and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the

supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the

premises where he carries on business in a manner so as to be easily accessible to any person wishing

to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as

mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision

as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements

as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission

from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the

concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price

notification and notes specified hereinabove, then the concerned manufacturer/marketing company

shall be liable to deposit the overcharged amount along with the interest thereon under the provisions

of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above

table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the

above said date of notification, stand(s) superseded.

[PN/190/58/2018/F/ F. No. 8(58)/2018/D.P./NPPA-Div.-II]

BALJIT SINGH,Assistant Director

vkns’k

ubZ fnYyh] rkjh[k% 4 जुलाई] 2018

dk-vk- 3241¼v½-&vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds


lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa Øe’k% rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS%

lkj.kh

uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks csp jgs vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku djsaxsA ¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V vf/kdre ewY; dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk fofuekZrk Mhihlhvks] 2013 ds iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd vkSj djksa ds varj ds dkj.k vf/kdre [kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY; dks fujarj cuk, j[ksaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V esa vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA ¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA

dz-la-

vuqlwfpr fofufeZfr dk uke

[kqjkd :i ,oa izcyrk

bdkbZ vf/kdre dher ¼#-½

iqufoZyksdu vkns’k la- ,oa rkjh[k

ekStwnk dk- vk- la- ,oa rkjh[k

(1) (2) (3) (4) (5) (6) (7)

1. fMxksDlhu vksjy fyD;wbZM 0-05 fexzk-@fefy-

1 fefy- 1.19 31015/100/2017-ihvkbZ ewY; fu/kkZj.k

dh rkjh[k 07.05.2018

1461(v) fnukad 02.04.2018

(Ø-la- 263)

2. QwjkslhekbM vksjy fyD;wbZM 10 fexzk-@fefy-

1 fefy- 2.60 31015/101/2017-ihvkbZ ewY; fu/kkZj.k

dh rkjh[k 07.05.2018

1461(v) fnukad 02.04.2018

(Ø-la- 340)


¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxsA

[dka- la-@190@58/2018@,Q@Qk- la- 8¼58½@2018@Mhih@,uihih,&fMoh- II]


ORDER

New Delhi, 4th July , 2018

S.O. 3241(E).—In implementation of directions given in line with review orders issued by the Department

of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department

of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by

paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated

the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of

Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table

regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the

table below, except in respect of things done or omitted to be done before such supersession, the National

Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below

as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s)

specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

No.

Name of the

Scheduled

Formulation

Dosage form

& Strength

Unit Ceiling

Price

(Rs.)

Review Order

number and date

Existing SO

number and date

(1) (2) (3) (4) (5) (6) (7)


Note:

(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled

formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and

notified by the Government, shall revise the prices of all such formulations downward not exceeding the

ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the

ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall

continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the

Government on the ceiling price mentioned in column (5) of the above said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in

accordance with the ceiling price specified in column (5) of the above table as per provisions contained in

paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V

from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a

copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary

price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on

business in a manner so as to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the

above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall

apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the

DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in

respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,

2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled

formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or

import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to

the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to

deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in

this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of

notification, stand(s) superseded.

[PN/190/58/2018/F/F. No. 8(58)/2018/D.P./NPPA-Div.-II]

BALJIT SINGH, Assistant Director

1. Digoxin Oral Liquid

0.05mg/ml

1 ML 1.19 31015/100/2017-

Pricing dated

07.05.2018

1461(E) dated

02.04.2018 (at Sl.

No. 263)

2. Furosemide Oral Liquid

10mg/ml

1 ML 2.60 31015/101/2017-

Pricing dated

07.05.2018

1461(E) dated

02.04.2018 (at Sl.

No. 340)


vkns’k

ubZ fnYyh] 4 जुलाई, 2018 dk- vk- 3242(v).—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr

blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼8½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

dz-la-

fofufeZfr dk uke

[kqjkd :i ,oa izcyrk

bdkbZ vf/kdre dher ¼#-½

iqufoZyksdu vkns’k la- ,oa rkjh[k

ekStwnk dk- vk- la- ,oa rkjh[k

fofuekZrk vkSj foi.ku daiuh

(1) (2) (3) (4) (5) (6) (7) (8)

1. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy ¼,Vksdksj lhoh 10½

izR;sd gkMZ tsysfVu dSIlwy es% ,VksjokLVkfVu 10 fexzk-] DyksfiMksxzsy 75 fexzk-

1 dSIlwy

10.92 31015/09/2018- ewY; fu/kkZj.k dh

fnukad 29.05.2018

3915(v) fnukad

18.12.2017

(Ø-la- 50)

eSllZ foaMykl ck;ksVsd izk- fy- @ eSllZ MkW- jsM~Mht yscksjsVjht

fy-

2. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy ¼,Vksdksj lhoh 20½

izR;sd gkMZ tsysfVu dSIlwy es% ,VksjokLVkfVu 20 fexzk-] DyksfiMksxzsy 75 fexzk-

1 dSIlwy

15.625 31015/09/2018- ewY; fu/kkZj.k dh

fnukad 29.05.2018

02(v) fnukad 01.01.2018

(Ø-la- 10)

eSllZ foaMykl ck;ksVsd izk- fy- @ eSllZ MkW- jsM~Mht

yscksjsVjht fy

3. VsyfelkVZu DyksjFkkyhMksu xksyh ¼fVxkVsy lh,p 80½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 80 fexzk-] DyksjFkkyhMksu vkbZih 12-5 fexzk-

1 xksyh

13.06 31015/13/2018- ewY; fu/kkZj.k dh

fnukad 29.05.2018

02(v) fnukad 01.01.2018

(Ø-la- 04)

eSllZ lu QkekZ

yscksjsVjht fy-

4. lsfQDlhe vksQ~yksDlklhu xksyh ¼jkuhDlhe Iyl½

izR;sd fQYe fyfir xksyh esa% lsfQDlhe fVªgkbMªsV ds cjkcj

1 xksyh

10.59 31015/06/2018- ewY; fu/kkZj.k dh

fnukad 29.05.2018

3915(v) fnukad

18.12.2017

(Ø-la- 40)

eSllZ Fksvksu QkekZL;wfVdYl baMLVªht fy-


uksV %

¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA ¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mi;qZDr tsusjfd@leku lajpuk okyk dksbZ Hkh czkaM@ lacaf/kr fofufeZfr;ksa dh izcyrk rFkk ljdkj }kjk fu/kkZfjr ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr dsUnzh;@jkT; ykblsflax

lsfQDlhe ,ugkbMªkst vkbZih 200 fexzk-


izR;sd gkMZ tsysfVu dSIlwy es% jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstwokLVkfVu 20 fexzk-] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-

1 dSIlwy

16.60 31015/12/2018- ewY; fu/kkZj.k dh

fnukad 08.06.2018

02(v) fnukad 01.01.2018

(Ø-la- 14)

eSllZ lk;uksdse

QkekZL;wfVdYl fy-@eSllZ

bfjt ykbQlkbalst

fy-


izR;sd gkMZ tsysfVu dSIlwy es% jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstwokLVkfVu 20 fexzk-] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-

1 dSIlwy

16.06 31015/14/2018- ewY; fu/kkZj.k dh

fnukad 29.05.2018

02(v) fnukad 01.01.2018

(Ø-la- 05)

eSllZ lk;uksdse

QkekZL;wfVdYl fy-@ eSllZ tsMl

gsYFkds;j fy-


vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA ¼N½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

[dka- la-@190@58/2018@,Q@Qk- la0 8¼58½@2018@Mhih@,uihih,&fMoh-II]


ORDER

New Delhi, the 4th

July , 2018

S. O. 3242 (E).—In implementation of directions given in line with review orders issued by the Department of

Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of

Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by

paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th

May, 2013 and

S. O. 701(E) dated 10th

March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and

in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National

Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing

Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as

the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding

entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company , as

specified in the corresponding entries in columns (3), (4) and (8) thereof;

TABLE

Sl.

No.

Name of the

Formulation

Dosage form &

Strength

Unit Retail

Price

(Rs.)

Review Order

number and

date

Existing SO

number &

date

Manufacturer &

Marketing

Company

respectively

(1) (2) (3) (4) (5) (6) (7) (8)

1. Atorvastatin +

Clopidogrel

Capsule

(Atocor CV 10)

Each hard gelatin

capsule contains:

Atorvastatin 10mg

Clopidogrel 75mg

1

Capsule

10.92 31015/09/2018-

Pricing dated

29.05.2018

3915(E) dated

18.12.2017

(at Sl. No. 50)

M/s Windlas Biotech

Pvt. Ltd. / M/s Dr.

Reddy’s

Laboratories Ltd.

2. Atorvastatin +

Clopidogrel

Capsule

(Atocor CV 20)

Each hard gelatin

capsule contains:

Atorvastatin 20mg

Clopidogrel 75mg

1

Capsule

15.625 31015/09/2018-

Pricing dated

29.05.2018

02(E) dated

01.01.2018

(at Sl. No. 10)

M/s Windlas Biotech

Pvt. Ltd. / M/s Dr.

Reddy’s

Laboratories Ltd.

3. Telmisartan +

Chlorthalidone

Tablet

(Tigatel CH 80)

Each film coated tablet

contains:

Telmisartan IP 80mg

Chlorthalidone IP

12.5mg

1

Tablet

13.06 31015/13/2018-

Pricing dated

29.05.2018

02(E) dated

01.01.2018

(at Sl. No. 04)

M/s Sun Pharma

Laboratories Limited

4. Cefixime +

Ofloxacin

Tablet

(Ranixime

Plus)

Each film coated tablet

contains:

Cefixime Trihydrate

eq. to Cefixime

anhydrous IP 200mg,

Ofloxacin IP 200mg

1

Tablet

10.59 31015/6/2018-

Pricing dated

29.05.2018

3915(E) dated

18.12.2017

(at Sl. No. 40)

M/s Theon

Pharmaceuticals

Limited / M/s Sun

Pharmaceutical

Industrial Limited

5. Rosuvastatin +

Clopidogrel

Capsule

Each hard gelatin

capsule contains:

Rosuvastatin Calcium

IP eq. to Rosuvastatin

20mg,

Clopidogrel

1

Capsule

16.60 31015/12/2018-

Pricing dated

08.06.2018

02(E) dated

01.01.2018

(at Sl. No. 14)

M/s Synokem


/ M/s Eris



Bisulphate IP eq. to

Clopidogrel 75mg

6. Rosuvastatin +

Clopidogrel

Capsule

Each hard gelatin

capsule contains:

Rosuvastatin Calcium

IP eq. to Rosuvastatin

20mg (As pellets)

Clopidogrel

Bisulphate IP eq. to

Clopidogrel 75mg (As

pellets)

1

Capsule

16.06 31015/14/2018-

Pricing dated

29.5.2018

02(E) dated

01.01.2018

(at Sl. No. 5)

M/s. Synokem


/

M/s Zydus

Healthcare

Ltd.

Note:

(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013

shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the

Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in

accordance with the retail price specified in column (6) of the above table as per provisions contained in

paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification

as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller

and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price

list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business

in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail prices are applicable only to the manufacturer / marketeer as mentioned above for

generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all

the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including

manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as

may be applicable, by the concerned manufacturers/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification

and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit

the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the

Essential Commodities Act, 1955.

[PN/190/58/2018/F/F. No. 8(58)/2018/D.P./NPPA-Div.-II]

BALJIT SINGH, Assistant Director

Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064

and Published by the Controller of Publications, Delhi-110054.

vkns’k ubz fnyyh] ] 2018dpco2013.com/files/data/gazattenotification2018/5151532326242.pdf · 2...

Documents